Hot Investor Mandate 3: Evergreen Fund Invests in Early Stage Devices, Therapeutics, and Diagnostics

6 Oct

An early-stage investment and development firm located in the US Mountain West has more than $300 million in assets and operates under an “Evergreen” structure. The firm is flexible in investment size and structure, but prefer initial investments in the $1M – $3M range.

The firm invests in medical devices, therapeutics, diagnostics and research tools. RCT focuses on medical devices that can be approved under the 510(k) guidelines, and prefers therapeutic product generating platforms and research tools platforms. For therapeutics, RCT prefers investments at an early-stage, from pre-clinical up to Phase I.

The firm seeks to invest in small, early-stage companies with a lean but strong and qualified management / execution team. The firm prefers to invest in companies in the U.S., but will consider opportunities in Europe, Israel and Australia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: